Treatment-related Mortality in Children with Cancer in Low-income and Middle-income Countries: a Systematic Review and Meta-analysis
Overview
Authors
Affiliations
Background: Approximately 90% of children with cancer live in low-income and middle-income countries (LMICs), where 5-year survival is lower than 20%. Treatment-related mortality in high-income countries is approximately 3-5%; however, in LMICs, treatment-related mortality has been reported in up to 45% of children with cancer. This study aimed to systematically explore the burden of treatment-related mortality in children with cancer in LMICs and to explore the association between country income level and treatment-related mortality.
Methods: For this systematic review and meta-analysis we identified articles published between Jan 1, 2010, and June 22, 2021, describing treatment-related mortality in paediatric patients (aged 0-21 years) with cancer in LMICs. We searched PubMed, Trip, Web of Science, Embase, and the WHO Global Metric Index databases. The search was limited to full-text articles and excluded case reports (<10 patients) and haematopoietic stem-cell transplantation recipients. Two reviewers independently screened studies for eligibility, extracted data from included publications, and evaluated data quality. Random and mixed-effects models were used to estimate treatment-related mortality burden and trends. The Cochran-Q statistic was used to assess heterogeneity between studies. This study is registered on PROSPERO (CRD42021264849).
Findings: Of 13 269 identified abstracts, 501 studies representing 68 351 paediatric patients with cancer were included. The treatment-related mortality estimate was 6·82% (95% CI 5·99-7·64), accounting for 30·9% of overall mortality (4437 of 14 358 deaths). Treatment-related mortality was inversely related to country income. Treatment-related mortality was 14·19% (95% CI 9·65-18·73) in low-income countries, 9·21% (7·93-10·49) in lower-middle-income countries, and 4·47% (3·42-5·53) in upper-middle-income countries (Cochran-Q 42·39, p<0·0001). In upper-middle-income countries, the incidence of treatment-related mortality decreased over time (slope -0·002, p=0·0028); however, outcomes remained unchanged in low-income (p=0·21) and lower-middle-income countries (p=0·16).
Interpretation: Approximately one in 15 children receiving cancer treatment in LMICs die from treatment-related complications. Although treatment-related mortality has decreased in upper-middle-income countries over time, it remains unchanged in LMICs. There is an urgent need for targeted supportive care interventions to reduce global disparities in childhood cancer survival.
Funding: American Lebanese Syrian Associated Charities and National Cancer Institute.
Pharmacological inhibition of the MAP2K7 kinase in human disease.
Lacorazza H Front Oncol. 2024; 14:1486756.
PMID: 39717752 PMC: 11663940. DOI: 10.3389/fonc.2024.1486756.
Sniderman E, Reljic T, Bhakta M, Bonilla M, Clyce J, Farmer J Cancer Med. 2024; 13(21):e70377.
PMID: 39499026 PMC: 11536432. DOI: 10.1002/cam4.70377.
Schulz J, Zalavari L, Gutkin P, Jiang A, Wang Y, Gibson C Front Oncol. 2024; 14:1405433.
PMID: 39439954 PMC: 11493730. DOI: 10.3389/fonc.2024.1405433.
Global disparities in cancer supportive care: An international survey.
Chan A, Eng L, Jiang C, Dagsi M, Ke Y, Tanay M Cancer Med. 2024; 13(17):e70234.
PMID: 39268694 PMC: 11393557. DOI: 10.1002/cam4.70234.
Treatment-related mortality in childhood cancer patients - who, when and how much.
Oskarsson T, Baecklund F Acta Oncol. 2024; 63:532-534.
PMID: 38946289 PMC: 11332546. DOI: 10.2340/1651-226X.2024.40315.